NinePoint Medical, a Cambridge, Mass.-based company that develops medical devices enabling high resolution in-vivo imaging, completed a $34m Series B financing.
The round was led by Corning Inc. (NYSE: GLW), with participation from founding investors Third Rock Ventures and Prospect Venture Partners. In conjunction with the funding, Curt Weinstein from Corning, and independent directors Tom Miller and Mark Stautberg, joined NinePoint’s board.
The company intends to use the funds to expand commercialization of its NvisionVLE™ Imaging System in the U.S., as well as develop its product offering.
Led by Charles S. Carignan, M.D., president and CEO, NinePoint Medical provides the NvisionVLE Imaging System, which enables physicians and pathologists to endoscopically view real-time, high-resolution, volumetric images of organs and tissues up to 3mm deep at better than 10 micron resolution.
Originally developed at the Wellman Center for Photomedicine at The Massachusetts General Hospital (MGH), the company licensed the imaging technology from MGH in 2010.